Roche Updates Late-Stage Pipeline; Highlights Drugs Outside Core Cancer Focus

Swiss drugmaker Roche will highlight its most promising treatments in oncology, immunology and ophthalmology at an investor event on Tuesday, as it seeks to show its potential in and beyond its core cancer expertise. The world's biggest maker of cancer medicines cited etrolizumab in inflammatory bowel disease and lampalizumab, a treatment for the dry form of age-related macular degeneration (AMD), as among its most promising therapies. The Basel-based firm is also developing so-called "follow on" drugs that it hopes will replace or breathe new life into old cancer products.

Help employers find you! Check out all the jobs and post your resume.